Humasis Co. Ltd. Logo

Humasis Co. Ltd.

205470.KQ

(0.0)
Stock Price

1.685,00 KRW

-20.31% ROA

-23.33% ROE

-3.03x PER

Market Cap.

236.361.610.934,00 KRW

0% DER

0% Yield

-462.67% NPM

Humasis Co. Ltd. Stock Analysis

Humasis Co. Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Humasis Co. Ltd. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Humasis Co. Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Humasis Co. Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Humasis Co. Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Humasis Co. Ltd. Revenue
Year Revenue Growth
2019 9.150.651.640
2020 45.717.211.980 79.98%
2021 321.829.140.750 85.79%
2022 471.272.761.010 31.71%
2023 15.496.824.320 -2941.09%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Humasis Co. Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2019 1.472.644.830
2020 1.529.271.390 3.7%
2021 3.373.130.830 54.66%
2022 5.234.781.890 35.56%
2023 4.217.872.236 -24.11%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Humasis Co. Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 37.299.790
2020 37.765.790 1.23%
2021 43.804.560 13.79%
2022 234.156.020 81.29%
2023 55.189.440 -324.28%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Humasis Co. Ltd. EBITDA
Year EBITDA Growth
2019 -280.209.790
2020 26.117.171.870 101.07%
2021 195.575.918.060 86.65%
2022 219.568.525.370 10.93%
2023 2.089.354.680 -10408.92%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Humasis Co. Ltd. Gross Profit
Year Gross Profit Growth
2019 3.924.741.900
2020 30.849.879.330 87.28%
2021 210.221.983.710 85.33%
2022 255.822.534.480 17.83%
2023 11.942.314.040 -2042.15%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Humasis Co. Ltd. Net Profit
Year Net Profit Growth
2019 -1.226.234.510
2020 20.937.242.310 105.86%
2021 151.204.591.720 86.15%
2022 182.626.628.060 17.21%
2023 4.984.208.960 -3564.1%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Humasis Co. Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 -11
2020 161 106.88%
2021 1.105 85.52%
2022 1.395 20.73%
2023 40 -3385%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Humasis Co. Ltd. Free Cashflow
Year Free Cashflow Growth
2019 -2.207.507.550
2020 -783.179.370 -181.86%
2021 186.962.245.690 100.42%
2022 158.086.339.070 -18.27%
2023 -44.571.431.150 454.68%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Humasis Co. Ltd. Operating Cashflow
Year Operating Cashflow Growth
2019 779.575.000
2020 14.297.964.970 94.55%
2021 205.023.365.610 93.03%
2022 202.596.059.180 -1.2%
2023 -22.340.706.900 1006.85%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Humasis Co. Ltd. Capital Expenditure
Year Capital Expenditure Growth
2019 2.987.082.550
2020 15.081.144.340 80.19%
2021 18.061.119.920 16.5%
2022 44.509.720.110 59.42%
2023 22.230.724.250 -100.22%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Humasis Co. Ltd. Equity
Year Equity Growth
2019 15.243.985.790
2020 48.684.310.860 68.69%
2021 202.005.961.740 75.9%
2022 346.733.946.030 41.74%
2023 315.598.421.210 -9.87%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Humasis Co. Ltd. Assets
Year Assets Growth
2019 36.487.810.680
2020 68.207.128.610 46.5%
2021 340.714.507.070 79.98%
2022 467.534.159.520 27.13%
2023 377.979.775.440 -23.69%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Humasis Co. Ltd. Liabilities
Year Liabilities Growth
2019 21.243.824.890
2020 19.522.817.750 -8.82%
2021 138.708.545.320 85.93%
2022 120.800.213.480 -14.82%
2023 62.381.354.220 -93.65%

Humasis Co. Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
132.75
Net Income per Share
-614.19
Price to Earning Ratio
-3.03x
Price To Sales Ratio
14.29x
POCF Ratio
-3.39
PFCF Ratio
-1.93
Price to Book Ratio
0.73
EV to Sales
13.97
EV Over EBITDA
-3.3
EV to Operating CashFlow
-3.39
EV to FreeCashFlow
-1.89
Earnings Yield
-0.33
FreeCashFlow Yield
-0.52
Market Cap
236,36 Bil.
Enterprise Value
231,13 Bil.
Graham Number
5916.17
Graham NetNet
1550

Income Statement Metrics

Net Income per Share
-614.19
Income Quality
0.89
ROE
-0.23
Return On Assets
-0.2
Return On Capital Employed
-0.24
Net Income per EBT
0.89
EBT Per Ebit
1.15
Ebit per Revenue
-4.54
Effective Tax Rate
0.12

Margins

Sales, General, & Administrative to Revenue
0.01
Research & Developement to Revenue
0.32
Stock Based Compensation to Revenue
0
Gross Profit Margin
-2.84
Operating Profit Margin
-4.54
Pretax Profit Margin
-5.23
Net Profit Margin
-4.63

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-547.96
Free CashFlow per Share
-983.82
Capex to Operating CashFlow
0.8
Capex to Revenue
-3.28
Capex to Depreciation
-10.65
Return on Invested Capital
-0.34
Return on Tangible Assets
-0.2
Days Sales Outstanding
32.7
Days Payables Outstanding
2.8
Days of Inventory on Hand
166.58
Receivables Turnover
11.16
Payables Turnover
130.26
Inventory Turnover
2.19
Capex per Share
-435.86

Balance Sheet

Cash per Share
1.928,71
Book Value per Share
2.532,79
Tangible Book Value per Share
2523.82
Shareholders Equity per Share
2532.79
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.07
Current Ratio
4.55
Tangible Asset Value
314,48 Bil.
Net Current Asset Value
216,29 Bil.
Invested Capital
0
Working Capital
217,49 Bil.
Intangibles to Total Assets
0
Average Receivables
1,27 Bil.
Average Payables
0,45 Bil.
Average Inventory
27952367140
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Humasis Co. Ltd. Dividends
Year Dividends Growth
2022 200

Humasis Co. Ltd. Profile

About Humasis Co. Ltd.

Humasis Co. Ltd. develops, manufactures, and markets in-vitro diagnostics for the detection of cardiac marker, fertility hormone, infectious disease, tumor marker, and cotinine for home and laboratory use in South Korea and internationally. It offers pregnancy and ovulation self-test products; Hubi-Quan Pro, a self-contained and cartridge reader to provide rapid quantitative results for membrane-based lateral flow immunochromatographic assays; and various rapid test kits. The company was founded in 2000 and is based in Anyang, South Korea.

CEO
Sung-gon Kim
Employee
175
Address
504, Shinwon Vision Tower
Anyang, 431-836

Humasis Co. Ltd. Executives & BODs

Humasis Co. Ltd. Executives & BODs
# Name Age
1 Sung-gon Kim
Chief Executive Officer
70

Humasis Co. Ltd. Competitors

LabGenomics Co., Ltd. Logo
LabGenomics Co., Ltd.

084650.KQ

()
Seegene, Inc. Logo
Seegene, Inc.

096530.KQ

(0.0)
Access Bio, Inc. Logo
Access Bio, Inc.

950130.KQ

()
Kolmar BNH Co., Ltd. Logo
Kolmar BNH Co., Ltd.

200130.KQ

(0.0)